Stroke, statins, and cholesterol. A meta-analysis of randomized, placebo-controlled, double-blind trials with HMG-CoA reductase inhibitors
Blauw GJ, Lagaay AM, Smelt AH, Westendorp RG
Stroke · 160 citas
Etiquetas de revisión
Financiación no declaradaDatos neutrales que nuestra revisión registró sobre cómo se hizo este estudio. Describen el método, nunca si nos gusta el resultado.
Cómo se estudió
- Diseño
- Metaanálisis (indexado por PubMed)
- Estudiado en
- Personas
- Resultado principal
- Eventos clínicos como enfermedad o muerte
Quién lo pagó
- Financiación
- Financiación no declarada
Publicación
- Publicado
- 1997-05-01 · Stroke · vol. 28 · número 5 · págs. 946–950
- Editorial
- Lippincott Williams & Wilkins
- Citado
- 311 citas · más que el 100% de estudios similares · 28.1× el promedio de su campo
- Impacto
- Entre el 10 % más citado de su campo
- Referencias
- 32 trabajos
- Acceso
- De pago
- Áreas de investigación
- Lipoproteins and Cardiovascular Health · Acute Ischemic Stroke Management · Cancer, Lipids, and Metabolism
- Palabras clave
- statins, stroke prevention, cholesterol, hypercholesterolemia, middle-aged adults, lipid-lowering therapy
- MeSH
- humans, cerebrovascular disorders, cholesterol, placebos, hydroxymethylglutaryl-coa reductase inhibitors, incidence, risk factors, double-blind method, aged, middle aged, randomized controlled trials as topic
4 autores
- Gerard J. Blauw🇳🇱Leiden University Medical Center
- A. Margot Lagaay🇳🇱Leiden University Medical Center
- Augustinus H. M. Smelt🇳🇱Leiden University Medical Center
- Rudi G. J. Westendorp🇳🇱Leiden University Medical Center
Resumen
El texto original del estudio, en el idioma en que se publicó.
Background and purpose
To estimate the effect of 3-hydroxy-3-methylglutaryl-coenzyme A (HMG-CoA) reductase inhibitors ("statins") on stroke ris, we combined the data of the randomized, placebo-controlled, double-blind trials with HMG-CoA reductase inhibitors published so far.
Methods
The studies were identified using the Medline CD+ and Current Contents databases from January 1980 through May 1996, inclusive. All studies were evaluated on the use of a placebo control, monotherapy, and double blindness. When the type of stroke or the occurrence of clinical events or adverse effects were incompletely or not reported, the investigators were contacted personally. For each trial, the number of strokes in the treatment arm was compared with the number of strokes expected on all observations under the assumption that drug treatment had no effect.
Results
A total of 462 strokes among 20438 participants in 13 trials could be analyzed. A total of 181 strokes were observed in patients randomized to treatment with an HMG-CoA reductase inhibitor and 261 strokes in patients randomized to placebo. A lower than expected number of strokes was observed in the treatment groups of all but one trial (P = .001). Treatment with an HMG-CoA reductase inhibitor led to an overall risk reduction of 31% (odds ratio, 0.69; 95% confidence interval, 0.57 to 0.83).
Conclusions
The combined data suggest that treatment with HMG-CoA reductase inhibitors prevents stroke in middle-aged persons. Because stroke is especially common in older age, these data reinforce the need for clinical trials to evaluate the effect of HMG-CoA reductase inhibitors in preventing stroke in the elderly.
Resumen vía Europe PMC. Los derechos de autor siguen siendo de los autores o la editorial.
Confianza de la comunidad
Cargando…
¿Cuánto confías en los hallazgos de este estudio?
Comentarios
¿Algo está mal aquí?
Señala este estudio si su información, etiquetas o financiación parecen incorrectas. Un editor revisa cada señalamiento.
Información educativa sobre investigación publicada. No es consejo médico ni una recomendación para empezar o dejar nada.